ProTIPNCT06979492
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial status changed: Recruiting → Withdrawn Sponsor's reason: The study was withdrawn due to no enrollment Show 7 more changesShow less
- Enrollment target: estimated 50 to confirmed 0
- Start date: Apr 2026 to Sep 2026
- Eligibility criteria expanded, about 12 words
- Primary endpoints: details revised at 1 of 5 entries
- Trial arms changed: 2 → 3
- Secondary endpoints: 11 to 12
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Dec 2025 to Apr 2026
- Site details revised
- Notable Start date: Aug 2025 to Dec 2025v3
- Notable Start date: Jun 2025 to Aug 2025
- Primary endpoints revised (5)
- Secondary endpoints revised (11)
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Secondary (12)
Show 7 moreShow less
Arms and interventions
Patients randomized to the control group will receive standard care for SCD alone. As part of the standard of care, women with SCD who become pregnant and who are on hydroxyurea (HU) will have the HU suspended by their primary SCD provider.
Participants will receive a blood transfusion between 6 and 20 weeks of gestation. It will be repeated at 3-6 week intervals, aiming to maintain HbS \<30%
Research testing on discarded, deidentified samples (placentas) of up to 10 women whose placentas were deemed normal, healthy, and full term by a clinical pathologist.
Biologicals: Prophylactic Transfusion Intervention group: Transfusion
Other: Control group
Sites
1 site in 1 country
- Grady Health SystemAtlanta, Georgia, United States